Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective lowered by Canaccord Genuity Group from $57.00 to ...

On Friday, Tandem Diabetes Care Inc (TNDM) stock saw a decline, ending the day at $30.6 which represents a decrease of $-2.72 or -8.16% from the prior close of $33.32. The stock opened at $33.71 and ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We are living in exciting ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report), with a price ...

During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Equities research analysts at Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Free ...

Diabetes costs US employers over $106B in lost productivity. Learn how data-driven support can improve employee health and ...

Discover the latest findings from the CDC on the growing prevalence of adult diabetes in the US, including key factors such as age, weight and education levels.

Bernstein has recently initiated Tandem Diabetes Care Inc (TNDM) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on October 4, 2024, Goldman had initiated the stock to ...

Tandem Diabetes Care Inc (TNDM) achieves highest quarterly sales in history, driven by strong US and international growth, ...